AroCell has announced that Cecilia Ahlin joins the management team as Chief Medical Officer.
Cecilia Ahlin will lead and develop AroCell’s clinical strategy with focus on getting more clinical evidence for the use of TK1 as a biomarker in cancer treatment.
Still an active oncologist treating patients
Ahlin has over 20 years of experience treating cancer patients and has a PhD in prognostic factors in breast cancer. She became a specialist in general oncology in 2003 and in gynecological oncology in 2011. She has experience from the Swedish MPA as clinical assessor and most recently from Novartis where she was Medical Head Oncology Sweden. Cecilia holds an associate professorship in Oncology at Örebro University.
“I’m very glad that we are able to attract such an experienced oncologist to our management team. Cecilia will contribute with her deep knowledge and insights of praxis in breast cancer treatment and in other tumors. She will be responsible for our clinical strategy with focus on getting more clinical evidence for using AroCell TK 210 ELISA in clinical settings,” says Michael Brobjer, CEO at AroCell. “Cecilia’s long clinical experience and the fact that she still is an active oncologist treating patients, gives me the confidence that AroCell will deliver assays suitable for clinical use.”
“I look forward to working with AroCell in the role of CMO and to make AroCell TK 210 ELISA standard of care for the treatment of cancer patients. Together with the management team, I will continue to strengthen AroCell’s clinical research program and our collaborations with external stakeholders. The target is to generate additional data on Thymidine Kinase 1 (TK1) both as a prognostic/predictive biomarker as well as a response biomarker for personalized oncology.” says Cecilia Ahlin.